- Home
- GGT vs TLSA Comparison
GGT vs TLSA Comparison
Compare GGT & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGT | TLSA |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 155.2M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GGT | TLSA |
|---|---|---|
| Price | $3.99 | $1.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 298.6K | 129.0K |
| Earning Date | 01-01-0001 | 05-06-2025 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.75 | $0.73 |
| 52 Week High | $4.76 | $2.60 |
Technical Indicators
Market Signals| Indicator | GGT | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 44.40 |
| Support Level | $3.93 | $1.27 |
| Resistance Level | $4.29 | $1.59 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 19.74 | 30.00 |
Price Performance
Historical ComparisonAbout GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.